04/11/2025
An interesting new paper has just been published in Toxcon by et al— using AI modeling to explore the relationship between GLP-1 agonists and the duration of neuromodulators.
The model, which simulated over 25,000 cases, found that all GLP-1 agonists reduced the duration of Botulinum-A effect — regardless of whether it was used for aesthetic or medical purposes.
In chronic migraine, the effect dropped from around 14 weeks to about 12, and in masseter treatments, from about 20 weeks down to 16 or 17.
Interestingly, the degree of reduction varied by drug — with semaglutide showing the least impact and tirzepatide the most. Mechanistically, this was linked to GLP-1–induced changes in SNAP-25 phosphorylation and lean mass reduction.
I found this fascinating because it’s something I’ve been noticing in clinic — and many colleagues have mentioned the same.
Now, it’s really important to note — these results are exploratory and come entirely from computational modeling, not clinical trials.
This approach is common in early-stage research — it’s cost-effective, avoids animal studies, and helps identify what human studies might be most valuable next.
So while this doesn’t change clinical practice yet, it does highlight a potential drug–procedure interaction we should keep an eye on — and maybe rethink how we dose and schedule treatments for patients on GLP-1s
